Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03782116 · ClinicalTrials.gov registry record · NA
Stress Incontinence Trial With Elitone Device
A NA study of Stress Urinary Incontinence, sponsored by Elidah.
- Completed
- Registry status
- NA
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT03782116: Completed NA study of Stress Urinary Incontinence, sponsored by Elidah.
NCT03782116 is a NA study of Stress Urinary Incontinence that has completed, run by Elidah. The registered enrollment target is 87 participants, below the 160-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03782116, a NA study of Stress Urinary Incontinence, has completed, sponsored by Elidah.
- COMPLETED
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized controlled study in which subjects are assigned to either a treatment group or a control (sham) group. Pre- and post-study outcome measures evaluate the change in incontinence episodes on women with mild-moderate stress urinary incontinence.
Primary Outcome
The percent reduction in average number of urinary incontinence episodes over 12 weeks.
Conditions Studied
Interventions
- DEVICE Transcutaneous electrical stimulation (Elitone)
Study Locations (1)
Connecticut
- Nationwide At-Home study - Monroe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2019-03-31 |
| Phase | NA |
What the finished NCT03782116 record still lists
NCT03782116 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 160-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Stress Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Transcutaneous electrical stimulation (Elitone) is the first listed.
NCT03782116 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03782116 about?
NCT03782116 is a clinical study titled "Stress Incontinence Trial With Elitone Device". This is a randomized controlled study in which subjects are assigned to either a treatment group or a control (sham) group. Pre- and post-study outcome measures evaluate the change in incontinence episodes on women with mild-moderate stress urinary incontinence.
What is the current status of trial NCT03782116?
This trial is currently completed. It is a NA study. The enrollment target is 87 participants. The study started on 2018-09-01. Estimated completion is 2019-03-31.
What conditions does trial NCT03782116 study?
This clinical trial studies the following conditions: Stress Urinary Incontinence.
What interventions are being tested in trial NCT03782116?
The interventions under investigation include: Transcutaneous electrical stimulation (Elitone) (DEVICE).
Who is sponsoring clinical trial NCT03782116?
This trial is sponsored by Elidah, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03782116 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03782116's enrollment target sits among peer trials
87 20th of 35 higher than 16 of 35 other Stress Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stress Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ProACT Post-Approval Study
RECRUITING · NA
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.
RECRUITING · NA
-
Impact of Unrestrictive Exercise Following Mid-Urethral Sling Surgery
RECRUITING · NA
-
Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy
RECRUITING · NA
-
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI